Brainomix Secures £14 Million to Boost US Expansion
Deal News | Mar 20, 2025 | Business Cloud
Brainomix, an AI-powered imaging tool creator focusing on stroke and lung fibrosis, has secured £14 million in a Series C funding round to spearhead its expansion in the United States. Originating as a University of Oxford spinout, Brainomix aims to enhance its AI-powered technology portfolio, accelerating diagnoses and broadening access to treatments. Currently operating in over 20 countries and recognized by NICE, its technology benefits more than 1.5 million patients and is utilized in over 300 hospitals. The funding round was led by Parkwalk Advisors, with participation from the Boehringer Ingelheim Venture Fund and new investor Hostplus via the IP Group Hostplus Innovation Fund, supported by LifeSci Capital. Brainomix plans to expand its team and operations globally with a focus on solidifying its US presence, aided by its recent 10 FDA clearances.
Sectors
- Medical Technology
- Artificial Intelligence
Geography
- United Kingdom – Brainomix, the primary company in the article, is based in the UK and is expanding its operations from there.
- United States – Brainomix is targeting its expansion into the US market, as indicated by recent regulatory clearances and the focus of new funding.
Industry
- Medical Technology – This article is centered around Brainomix, a company focused on creating AI-powered imaging tools for medical use, specifically targeting stroke and lung fibrosis.
- Artificial Intelligence – The development and application of AI-powered platforms are central to Brainomix's mission, aiming to revolutionize diagnostics and treatment within healthcare.
Financials
- £14 million – Series C investment round completed by Brainomix to fuel US expansion and technology advancement.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Brainomix | Target company | Company | A University of Oxford spinout creating AI-powered imaging tools for stroke and lung fibrosis diagnostics. |
| Parkwalk Advisors | Investor | Company | The UK's largest growth EIS fund manager, co-leading the Series C funding round for Brainomix. |
| Boehringer Ingelheim Venture Fund (BIVF) | Investor | Company | A globally operating venture fund co-leading the investment round in Brainomix. |
| Hostplus via the IP Group Hostplus Innovation Fund | Investor | Company | A new investor supporting Brainomix's Series C funding round. |
| LifeSci Capital | Supporter | Company | Provided support for the Series C funding round for Brainomix. |
| Dr. Michalis Papadakis | CEO and co-founder | Person | CEO and co-founder of Brainomix, strategizing the company's expansion and innovation. |
| John Pearson | Chief investment officer | Person | Chief investment officer at Parkwalk, advocating for the firm’s investment in Brainomix. |